Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer.

Miller ET, Chamie K, Kwan L, Lewis MS, Knudsen BS, Garraway IP.

Cancer Med. 2017 Jan;6(1):163-172. doi: 10.1002/cam4.981.

2.

Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort.

Mithal P, Howard LE, Aronson WJ, Terris MK, Cooperberg MR, Kane CJ, Amling C, Freedland SJ.

BJU Int. 2016 Feb;117(2):244-8. doi: 10.1111/bju.13181.

3.

Adherence to performance measures and outcomes among men treated for prostate cancer.

Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Miller DC, Montgomery JS, Weizer AZ, Hollenbeck BK.

J Urol. 2014 Sep;192(3):743-8. doi: 10.1016/j.juro.2014.03.091.

4.

Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.

Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ.

BJU Int. 2012 Aug;110(4):492-8. doi: 10.1111/j.1464-410X.2011.10754.x.

5.

Clinically localised prostate cancer.

Wilt TJ, Thompson IM.

BMJ. 2006 Nov 25;333(7578):1102-6. Review. No abstract available.

Supplemental Content

Loading ...
Support Center